Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK208141 + non-MPL-containing adjuvant
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
GSK208141 + non-MPL-containing adjuvant is an investigational recombinant vaccine developed as a candidate immunotherapy for herpes simplex virus (HSV) infection. GSK208141 represents a recombinant glycoprotein D (gD)-based HSV vaccine and was tested with a non-MPL-containing adjuvant, meaning the adjuvant does not include monophosphoryl lipid A (MPL), a commonly used immune-stimulatory adjuvant. The vaccine aimed to induce an immune response against HSV in seropositive adults. The adjuvant was designed to enhance immunogenicity without MPL. Clinical trials tested safety, reactogenicity, and immunogenicity, as well as measured anti-HSV antibody formation and physical signs/symptoms in healthy HSV-positive adults. Development was discontinued after failing primary endpoints in trials.
- Other names
- Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant
02
Targets
HS (Heparan sulfate)TNFRSF14 (Tumor necrosis factor receptor superfamily member 14)NECTIN1 (Poliovirus receptor-related 1)gD (HSV-2 glycoprotein D)
Beyond the preview
Go deeper on GSK208141 + non-MPL-containing adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK208141 + non-MPL-containing adjuvant.